Novo Nordisk and Aarhus University team up on world-class talents

Novo NordiskNovo Nordisk and Aarhus University's Science and Technology faculty today signed a collaboration agreement to strengthen protein technology research and development. Under the new collaboration, a total of nine PhD students will be offered three-year research scholarships. The research will take place in the leading technological research environments at Science and Technology, Aarhus University, and in Novo Nordisk's research and development department in Måløv. The Aarhus Novo Nordisk Science and Talent Network programme will run for five years.

"This is the starting point for a stronger collaboration between Aarhus University and Novo Nordisk, which is exploiting the powerful and growing synergy between research and industrial development," says Niels Chr. Nielsen, dean of the Faculty of Science and Technology, Aarhus University. "The collaboration creates a unique opportunity to focus on talent development while uniting and further developing excellent research environments within the development of protein- and peptide-based medicines at Aarhus University and Novo Nordisk."

Aarhus University and Novo Nordisk are also seizing the opportunity to initiate collaboration on education. The intention is that students will have the opportunity to combine highly theoretical training directly with practical and industry-relevant problems.

"With this agreement, we are building an important relationship with some of the best research environments at Aarhus University in areas of technology that are significant to Novo Nordisk. Partnerships like this with leading research environments - and the training of talented young researchers - are important for driving innovation at Novo Nordisk," says Peter Kurtzhals, senior vice president, Global Research, Novo Nordisk.

Aarhus University belongs to the scientific elite and has, among other things, core competences within organic chemistry, protein chemistry and structural biology. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. Over 5,400 employees work in research and development at Novo Nordisk in Denmark, the US and China, many of them in partnership with external biotech and academic researchers. The company has about 120 PhD students and postdocs worldwide - and soon also some in Aarhus.

A joint steering committee with members from Aarhus University and Novo Nordisk will have overall responsibility for the programme. The first three PhD students are expected to begin their research in 2017.

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 75 countries and markets its products in more than 180 countries.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

MSD Innovation Factory is looking for digital solu…

MSD is looking for innovators to solve 7 health-related challenges. One of them seeks to support anaesthesiologists with their continuous education (e.g. at the operation...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]